[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349630-105":59,"doc-detail-349630-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","copy-number-variants-in-brca1-and-brca2-genes-in-polish-patients-with-breast-and-ovarian-cancer","Copy number variants in BRCA1 and BRCA2 genes in Polish patients with breast and ovarian cancer","","BRCA1 and BRCA2 are key susceptibility genes in hereditary breast and ovarian cancer (HBOC), where mutational status informs PARP inhibitor therapy. Although single-nucleotide variants are common, copy number variants (CNVs) show substantial population differences. This study determines the incidence of BRCA1/2 CNVs in Poland, addressing limited CNV testing data despite non-mandatory screening practices.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/copy-number-variants-in-brca1-and-brca2-genes-in-polish-patients-with-breast-and-ovarian-cancer/349630/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/copy-number-variants-in-brca1-and-brca2-genes-in-polish-patients-with-breast-and-ovarian-cancer/349630.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why focus on BRCA1 and BRCA2 copy number variants in HBOC?","Question",{"text":112,"@type":113},"BRCA1 and BRCA2 are central susceptibility genes in hereditary breast and ovarian cancer. Their mutational status helps guide PARP inhibitor therapy, and CNV prevalence can differ markedly by population.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were BRCA1/2 CNVs assessed in the Polish cohort?",{"text":117,"@type":113},"Results from genetic tests were retrospectively analyzed for 2,720 individuals tested between 2021 and 2024. Testing included DNA extraction, NGS, and MLPA confirmation, with variant classification following ACMG-AMP guidelines.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding BRCA2 and BRCA1 CNVs?",{"text":121,"@type":113},"No BRCA2 CNVs were identified. Pathogenic BRCA1 CNVs were detected in 0.85% overall (0.52% among cancer patients), spanning 23 individuals across 13 families, with eight distinct CNVs identified.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349630,1790507383,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Journal of Cancer Research and Clinical Oncology (2026) 152:175  \n[https://doi.org/10.1007/s00432-026-06527-4](https://doi.org/10.1007/s00432-026-06527-4)  \nRESEARCH  \nCopy number variants in BRCA1 and BRCA2 genes in Polish patients with breast and ovarian cancer  \nAnna Doraczynska-Kowalik1 · Rafal Matkowski2,3 · Dagmara Michalowska3 · Agnieszka Chrusciel3 · Mariola Semeniuk4 · Dorota Blomka3 · Paulina Lawicka3 · Ewelina Czykalko3 · Mariola Abrahamowska2,3 · Aleksandra Pietron3 · Gabriela Janus-Szymanska5,3 · Ireneusz Pawlak3 · Adam Maciejczyk2,3 ·  \nJolanta Szelachowska2,3 · Izabela Laczmanska4  \nReceived: 6 April 2026 / Accepted: 27 May 2026 © The Author(s) 2026  \nAbstract  \nPurpose BRCA1 and BRCA2 are key susceptibility genes in hereditary breast and ovarian cancer (HBOC), with mutational status guiding PARP inhibitor therapy. While single-nucleotide variants (SNVs) predominate, the prevalence of copy number variants (CNVs) varies significantly across different populations. This study aims to determine the incidence of BRCA1/2 CNVs in the Polish population, where data remain scarce due to non-mandatory CNV testing.  \nMethods We retrospectively analysed the results of genetic tests assessing the presence of BRCA1/2 CNVs performed in 2720 individuals tested at the Lower Silesian Oncology Centre (2021–2024), including 2702 breast/ovarian cancer patients and 18 unaffected relatives. The mean age was 54.7 ± 15.15 years. Genetic testing involved DNA extraction, NGS, and MLPA for CNV confirmation. Variants were classified according to ACMG-AMP guidelines and verified through independent testing.  \nResults In this study, no BRCA2 CNVs were identified, consistent with previous Central European findings. Pathogenic BRCA1 CNVs were detected in 0.85% of the analyzed cohort and in 0.52% of the cancer patient subgroup, affecting 23 individuals from 13 families. Eight distinct BRCA1 CNVs were detected, the most common being exon 21 deletion. Affected families exhibited a high incidence of HBOC-related cancers, with early-onset breast cancer and a notable proportion of triple-negative breast cancer cases.  \nConclusions This study highlights the clinical significance of BRCA1 CNVs in Polish patients with HBOC-spectrum cancersand their families. Although rare, these variants were associated with aggressive cancer phenotypes and early onset. Given their diagnostic and therapeutic implications, BRCA1 CNVs should be routinely analysed in high-risk families to ensure accurate detection and personalised treatment planning.  \nKeywords Breast and ovarian cancer · BRCA1 · BRCA2 · CNVs · MLPA · NGS  \n􀀍 Anna Doraczynska-Kowalik [anna.doraczynska-kowalik@umw.edu.pl](anna.doraczynska-kowalik@umw.edu.pl)  \n1 Department of Genetics, Faculty of Medicine, Wroclaw Medical University, Marcinkowskiego 1, 50-368 Wroclaw, Poland  \n2 Department of Oncology, Faculty of Medicine, Wroclaw Medical University, Hirszfelda 12, 53-413 Wroclaw, Poland  \n3 Lower Silesian Center of Oncology, Pulmonology and Hematology, Hirszfelda 12, 53-413 Wroclaw, Poland  \n4 Department of Clinical and Experimental Pathology, Faculty of Medicine, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland  \n5 Faculty of Medicine, Wroclaw University of Science and Technology, Grunwaldzki Sq. 11, 50-377 Wroclaw, Poland  \nIntroduction  \nHereditary predisposition to breast and ovarian cancer (HBOC) is one of the most commonly examined predispositions in Poland. Public funding ensures that many patients with breast, ovarian, pancreatic and prostate cancer and their families have access to genetic diagnostics ranging from testing for a single familial pathogenic variant, testing for a few selected pathogenic variants (most common in the Polish population), and also sequencing of the whole coding part of selected genes (Doraczynska-Kowalik et al. 2022) .  \nIt is estimated that even about 10–15% of breast cancer patients, 15% of ovarian cancer patients, 5–10% of  \npancreatic cancer patients, ","cbCaipzzpjwrTWPG","https://ap.wps.com/l/cbCaipzzpjwrTWPG","pdf",1194150,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n# Introduction\n## HBOC predisposition and genetic testing in Poland\n## Prevalence and clinical relevance of BRCA1/2 variants\n# Table 1 CNV proportions by population","[{\"question\":\"Why focus on BRCA1 and BRCA2 copy number variants in HBOC?\",\"answer\":\"BRCA1 and BRCA2 are central susceptibility genes in hereditary breast and ovarian cancer. Their mutational status helps guide PARP inhibitor therapy, and CNV prevalence can differ markedly by population.\"},{\"question\":\"How were BRCA1/2 CNVs assessed in the Polish cohort?\",\"answer\":\"Results from genetic tests were retrospectively analyzed for 2,720 individuals tested between 2021 and 2024. Testing included DNA extraction, NGS, and MLPA confirmation, with variant classification following ACMG-AMP guidelines.\"},{\"question\":\"What were the main findings regarding BRCA2 and BRCA1 CNVs?\",\"answer\":\"No BRCA2 CNVs were identified. Pathogenic BRCA1 CNVs were detected in 0.85% overall (0.52% among cancer patients), spanning 23 individuals across 13 families, with eight distinct CNVs identified.\"}]","Copy number variants in BRCA1 and BRCA2 genes in Polish patients with breast and ovarian cancer | PDF",1790084596,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0577691f147cc73e994d27d506c4c482.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a60a0768816e662d7c7dd7ae1e4da532.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8815007c2ecdbb0325717bc1056d6afe.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ed4cbac9447095127287b39fb2654ec.webp",980,1301]